The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC).
 
Mingjia Li
No Relationships to Disclose
 
Songzhu Zhao
No Relationships to Disclose
 
Kenneth Chian
No Relationships to Disclose
 
Hyunwoo Kwon
No Relationships to Disclose
 
Nicholas Jones
No Relationships to Disclose
 
Adam Khorasanchi
No Relationships to Disclose
 
Timothy Gauntner
No Relationships to Disclose
 
Christopher C. Coss
Patents, Royalties, Other Intellectual Property - Patent holder and royalty recipient from Recursion Pharmaceuticals concerning IP surrounding methods of use for the HDACi AR-42; Patent holder concerning IP discovered while employed by GTx INC
 
Mitch A. Phelps
Consulting or Advisory Role - DTx Pharma
 
Daniel Spakowicz
No Relationships to Disclose
 
Lai Wei
No Relationships to Disclose
 
Asrar Alahmadi
No Relationships to Disclose
 
Regan Michelle Memmott
Consulting or Advisory Role - Takeda
 
Jacob Kaufman
Consulting or Advisory Role - AstraZeneca
 
Kai He
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Geneplus; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Perthera
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)
 
Peter G. Shields
No Relationships to Disclose
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Bristol-Myers Squibb; Curio Science; EMD Serono; Genentech/Roche; GlaxoSmithKline; Intellisphere; InThought; Iovance Biotherapeutics; Janssen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Merck KGaA; Mirati Therapeutics; MSD Oncology; NCCN/AstraZeneca; Novartis; OncLive/MJH Life Sciences; Pfizer; PPD; Regeneron; Roche; Sanofi
 
Gregory Alan Otterson
Consulting or Advisory Role - Novocure; OncLive/MJH Life Sciences
Research Funding - Apollomics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst)
 
Carolyn J Presley
Consulting or Advisory Role - Jazz Pharmaceuticals; Jazz Pharmaceuticals; Onc Live; Regeneron
 
Dwight Hall Owen
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Onc.AI (Inst); Palobiofarma (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech